35.20
-0.39 (-1.10%)
| Previous Close | 35.59 |
| Open | 35.72 |
| Volume | 243,522 |
| Avg. Volume (3M) | 435,911 |
| Market Cap | 1,141,669,120 |
| Price / Earnings (TTM) | 17.25 |
| Price / Earnings (Forward) | 4.86 |
| Price / Sales | 1.88 |
| Price / Book | 3.75 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2026 |
| Profit Margin | 6.61% |
| Operating Margin (TTM) | 13.71% |
| Diluted EPS (TTM) | 1.22 |
| Quarterly Revenue Growth (YOY) | 22.70% |
| Quarterly Earnings Growth (YOY) | -91.30% |
| Total Debt/Equity (MRQ) | 411.94% |
| Current Ratio (MRQ) | 1.08 |
| Operating Cash Flow (TTM) | 198.44 M |
| Levered Free Cash Flow (TTM) | 341.32 M |
| Return on Assets (TTM) | 7.95% |
| Return on Equity (TTM) | 19.23% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Bullish |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Collegium Pharmaceutical, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | 0.5 |
| Average | 2.00 |
|
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 1.69% |
| % Held by Institutions | 117.12% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Eventide Asset Management, Llc | 31 Mar 2026 | 1,424,282 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |